CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ICOD project is developing a new therapy for cognitive deficits in individuals with Down syndrome using AEF0217, a drug targeting the CB1 receptor. This innovative treatment aims to improve cognitive function without causing behavioral side effects.
Cognitive disabilities in individuals with Down syndrome (DS), also known as Trisomy 21, have no approved pharmacological treatment and represent a significant burden on DS individuals, their families and the healthcare system.
The ICOD project will deliver a clinical proof of concept for a new therapy of cognitive deficits in DS by performing first in humans (phase I) and clinical efficacy (Phase II) studies with AEF0217. AEF0217 is a new chemical entity which offers a unique opportunity to tre…
CONSORCIO MAR PARC DE SALUT DE BARCELONA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, BORDEAUX
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
France, Saint Etienne
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
